Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

Key Takeaway: Arrowhead Pharmaceuticals has licensed its clinical MASH program targeting PNPLA3 to Madrigal Pharmaceuticals. This collaboration aims to advance the development of therapies related to this target. Further details on the financial terms or specific goals of the partnership were not disclosed.